Repligen Corp. (RGEN) Stock Price Up 3.9%
Repligen Corp. (NASDAQ:RGEN) rose 3.9% on Monday . The stock traded as high as $29.79 and last traded at $29.72, with a volume of 160,001 shares. The stock had previously closed at $28.60.
RGEN has been the topic of several recent research reports. Zacks Investment Research raised Repligen Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Jefferies Group reaffirmed a “hold” rating and issued a $28.00 price target on shares of Repligen Corp. in a research note on Monday, June 13th.
The company has a market cap of $1.00 billion and a price-to-earnings ratio of 124.46. The company has a 50 day moving average of $25.70 and a 200-day moving average of $25.35.
Repligen Corp. (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, May 5th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.10 by $0.02. The firm had revenue of $25.10 million for the quarter, compared to analysts’ expectations of $22.54 million. During the same quarter in the previous year, the business earned $0.12 earnings per share. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. On average, analysts anticipate that Repligen Corp. will post $0.47 EPS for the current fiscal year.
In other Repligen Corp. news, VP Howard Benjamin sold 2,889 shares of the firm’s stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $26.72, for a total transaction of $77,194.08. Following the transaction, the vice president now directly owns 18,626 shares in the company, valued at approximately $497,686.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas F. Ryan, Jr. sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $24.59, for a total value of $245,900.00. Following the transaction, the director now owns 27,094 shares in the company, valued at $666,241.46. The disclosure for this sale can be found here.
Other hedge funds and institutional investors recently made changes to their positions in the company. Matarin Capital Management LLC bought a new position in shares of Repligen Corp. during the fourth quarter worth about $4,489,000. Stephens Investment Management Group LLC increased its position in shares of Repligen Corp. by 26.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 435,006 shares of the company’s stock worth $12,306,000 after buying an additional 89,827 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in shares of Repligen Corp. by 157.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 102,105 shares of the company’s stock worth $2,888,000 after buying an additional 62,405 shares in the last quarter. Globeflex Capital L P increased its position in shares of Repligen Corp. by 50.6% in the fourth quarter. Globeflex Capital L P now owns 36,153 shares of the company’s stock worth $1,023,000 after buying an additional 12,153 shares in the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Repligen Corp. by 14.4% in the fourth quarter. Nationwide Fund Advisors now owns 82,025 shares of the company’s stock worth $2,320,000 after buying an additional 10,350 shares in the last quarter.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.